menu
    • menu
    [{"orgOrder":0,"company":"Belhaven Biopharma","sponsor":"Lovelace Biomedical","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Hormone","year":"2024","type":"Inapplicable","leadProduct":"Epinephrine","moa":"Adrenergic receptor","graph1":"Immunology","graph2":"Phase III","graph3":"Belhaven Biopharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Powder","sponsorNew":"Belhaven Biopharma \/ Lovelace Biomedical","highestDevelopmentStatusID":"10","companyTruncated":"Belhaven Biopharma \/ Lovelace Biomedical"},{"orgOrder":0,"company":"Belhaven Biopharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Hormone","year":"2025","type":"Inapplicable","leadProduct":"Epinephrine","moa":"Adrenergic receptor","graph1":"Immunology","graph2":"Phase III","graph3":"Belhaven Biopharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Powder","sponsorNew":"Belhaven Biopharma \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Belhaven Biopharma \/ Undisclosed"},{"orgOrder":0,"company":"Belhaven Biopharma","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Hormone","year":"2025","type":"Financing","leadProduct":"Epinephrine","moa":"Adrenergic receptor","graph1":"Immunology","graph2":"Phase III","graph3":"Belhaven Biopharma","amount2":0.01,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0.01,"dosageForm":"Powder","sponsorNew":"Belhaven Biopharma \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Belhaven Biopharma \/ Undisclosed"},{"orgOrder":0,"company":"Belhaven Biopharma","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Hormone","year":"2025","type":"Series A Financing","leadProduct":"Epinephrine","moa":"Adrenergic receptor","graph1":"Immunology","graph2":"Phase III","graph3":"Belhaven Biopharma","amount2":0.01,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0.01,"dosageForm":"Powder","sponsorNew":"Belhaven Biopharma \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Belhaven Biopharma \/ Undisclosed"}]

    Find Clinical Drug Pipeline Developments & Deals by Belhaven Biopharma

    Menu

    Belhaven Biopharma

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Belhaven Biopharma

                            U.S.A arrow
                            AAPS
                            Not Confirmed

                            Belhaven Biopharma

                            U.S.A arrow
                            AAPS
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Epinephrine

                            Therapeutic Area : Immunology

                            Study Phase : Phase III

                            Sponsor : Undisclosed

                            Deal Size : $10.0 million

                            Deal Type : Series A Financing

                            DEALS_DEV arrow-down

                            Belhaven Biopharma Closes Oversubscribed Series A for the Development of Nasdepi Program

                            Details : The proceeds from the Series A will enable Belhaven to complete the clinical development and commercial manufacturing of Nasdepi (epinephrine) for treatment of anaphylaxis.

                            Product Name : Nasdepi

                            Product Type : Hormone

                            Upfront Cash : Undisclosed

                            August 21, 2025

                            Lead Product(s) : Epinephrine

                            Therapeutic Area : Immunology

                            Highest Development Status : Phase III

                            Sponsor : Undisclosed

                            Deal Size : $10.0 million

                            Deal Type : Series A Financing

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Belhaven Biopharma

                            U.S.A arrow
                            AAPS
                            Not Confirmed

                            Belhaven Biopharma

                            U.S.A arrow
                            AAPS
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Epinephrine

                            Therapeutic Area : Immunology

                            Study Phase : Phase III

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Belhaven Reports Positive Nasdepi Dose Study in Allergic Rhinitis Patients

                            Details : Nasdepi is a dry powder formulation of epinephrine being developed for intranasal administration to treat Type 1 allergic reactions including anaphylaxis.

                            Product Name : Nasdepi

                            Product Type : Hormone

                            Upfront Cash : Inapplicable

                            April 15, 2025

                            Lead Product(s) : Epinephrine

                            Therapeutic Area : Immunology

                            Highest Development Status : Phase III

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Belhaven Biopharma

                            U.S.A arrow
                            AAPS
                            Not Confirmed

                            Belhaven Biopharma

                            U.S.A arrow
                            AAPS
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Epinephrine

                            Therapeutic Area : Immunology

                            Study Phase : Preclinical

                            Sponsor : Undisclosed

                            Deal Size : $11.0 million

                            Deal Type : Financing

                            DEALS_DEV arrow-down

                            Belhaven Raises $11M for Nasdepi(R), Nasal Breakthrough for Anaphylaxis

                            Details : The financing from the proceeds will support the development of Nasdepi (epinephrine). It is being evaluated for the treatment of Anaphylactic reactions due to severe allergies.

                            Product Name : Nasdepi

                            Product Type : Hormone

                            Upfront Cash : Undisclosed

                            January 22, 2025

                            Lead Product(s) : Epinephrine

                            Therapeutic Area : Immunology

                            Highest Development Status : Preclinical

                            Sponsor : Undisclosed

                            Deal Size : $11.0 million

                            Deal Type : Financing

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Belhaven Biopharma

                            U.S.A arrow
                            AAPS
                            Not Confirmed

                            Belhaven Biopharma

                            U.S.A arrow
                            AAPS
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Epinephrine

                            Therapeutic Area : Immunology

                            Study Phase : Preclinical

                            Sponsor : Lovelace Biomedical

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Belhaven Biopharma Supports Dry Powder Nasal Epinephrine Delivery Solution in Canine Study

                            Details : Nasdepi (epinephrine) a small molecule, dry powder nasal formulation is currently being investigated for the treatment of patients with anaphylactic reactions due to severe allergies.

                            Product Name : Nasdepi

                            Product Type : Hormone

                            Upfront Cash : Inapplicable

                            July 09, 2024

                            Lead Product(s) : Epinephrine

                            Therapeutic Area : Immunology

                            Highest Development Status : Preclinical

                            Sponsor : Lovelace Biomedical

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth